FDA Inspection 1327208 — Sefanit G. Gebretsadik
The FDA completed an inspection of Sefanit G. Gebretsadik on Jul 7, 2026 in Dallas, TX. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Jul 7, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Dallas, TX (United States)
Additional details
Clinical Investigator (CI)